Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Medical College of Wisconsin.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Medical College of Wisconsin
ClinicalTrials.gov Identifier:
NCT00677183
First received: May 9, 2008
Last updated: May 20, 2009
Last verified: May 2009

May 9, 2008
May 20, 2009
May 2008
May 2011   (final data collection date for primary outcome measure)
  • We will compare known frequencies from the Hapmap and specifically compare the proportions for those with NASH in adults to see if there is a difference in the child incidence of NASH. [ Time Frame: three years ] [ Designated as safety issue: No ]
  • We will compare the proportions of those with NASH to those without NASH and those with fibrosis compared to those without fibrosis. [ Time Frame: Three years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00677183 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
Development of a Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children

The purpose of this study is to document how often specific genotypes known to be associated with adult-onset NASH (Non-Alcoholic Steatohepatitis) occur in a pediatric cohort and investigate whether these genotypes are associated with increased susceptibility to NASH.

NASH is a clinico-pathological entity characterized by the development of histological changes of inflammation and fibrosis in the liver that are nearly identical to those induced by excessive alcohol intake, but in the absence of alcohol abuse. Nonalcoholic steatohepatitis occurs commonly children with additional comorbidities such as obesity and diabetes mellitus. Paralleling the increasing prevalence of obesity and type 2 diabetes in the pediatric population, nonalcoholic fatty liver disease (NAFLD) and especially its more severe histological form NASH, is expected to become one of the most common causes of end-stage liver disease in both children and young adults.

Although no genome wide association studies have been conducted in association with NASH to date, individual candidate gene investigations have identified several genes associated with increase susceptibility to NASH in adults including the microsomal triglyceride transfer protein (MTP) which regulates the incorporation of triglycerides into apolipoprotein B and a key enzyme for the assembly and secretion of VLDL from hepatocytes, the manganese superoxide dismutase (MnSOD) gene which catalyzes the conversion of two molecules of superoxide anion, a highly unstable ROS, into hydrogen peroxide and oxygen more stable ROS, and lastly, phosphatidylethanolamine N-methyltransferase (PEMT) which is required for hepatic secretion of triacylglycerol in very low density lipoproteins (VLDL).

We propose the following aim:

Aim 1: To document the frequency of specific genotypes, previously identified to be associated with adult-onset NASH, in a purely pediatric cohort.

Aim 2: To investigate whether these genotypes are associated with increased susceptibility to NASH and increased occurrence of fibrosis in the cohort of pediatric subjects. Our hypothesis would be:

A significantly higher proportion of the polymorphisms would exist in those subjects with NASH compared to controls.

Aim 3: To investigate the presence of other polymorphisms or other biomarker that are indicative of pediatric NASH. Such that our secondary hypothesis would be:

Specific polymorphisms or biomarkers will be identified that will indicate a higher probability of NASH.

Observational
Observational Model: Family-Based
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

10mL of blood will be retained from each participant and their parents. 5mL of this blood will undergo DNA extraction and genotyping for several known NASH related genes. The other 5mL of blood will be saved as serum for future analysis.

Non-Probability Sample

The child subjects will be recruited from the Hepatology Clinic at Children's Hospital of Wisconsin.

Non-Alcoholic Steatohepatitis
Not Provided
  • SN###.#1
    All children in this cohort will have biopsy-proven NASH.
  • SN###.#2
    This cohort will be parents (mother and father when possible) of child subjects with biopsy-proven NASH.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All subjects aged 2-18 with biopsy proven NAFLD and/or NASH undergoing a blood draw and willing to consent to this study will qualify for inclusion in this protocol.

Exclusion Criteria:

  • other causes of chronic liver disease or other chronic diseases, specifically autoimmune disorders, immunodeficiencies, or individuals with congenital/genetic disorders
  • chronic viral hepatitis, Wilson's disease, or alpha -1- antitrypsin deficiency
  • acute life threatening illness or conditions
Both
2 Years to 18 Years
No
Contact: Vincent F Biank, MD 414-266-3690 vbiank@mcw.edu
Contact: Grzegorz Telega, MD 414-266-3690 gtelega@mcw.edu
United States
 
NCT00677183
CHW 08/36, GC 618
No
Vincent Biank/Principal Investigator, Medical College of Wisconsin
Medical College of Wisconsin
Not Provided
Principal Investigator: Vincent F Biank, MD Medical College of Wisconsin
Medical College of Wisconsin
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP